RHHBF
Get informed when a big investor buys or sells
+ FollowJuly 25, 2024 - AI Summary
Undervalued by 6.1% based on the discounted cash flow analysis.
| Market cap | $363.74 Billion |
|---|---|
| Enterprise Value | $389.95 Billion |
| Dividend Yield | $12.41 (2.73%) |
| Earnings per Share | $16.19 |
| Beta | 0.35 |
| Outstanding Shares | 809,257,000 |
| P/E Ratio | 23.35 |
|---|---|
| PEG | -299.59 |
| Price to Sales | 2.9 |
| Price to Book Ratio | 9.81 |
| Enterprise Value to Revenue | 3.16 |
| Enterprise Value to EBIT | 13.17 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.97 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...